Your browser doesn't support javascript.
loading
The Role of Social Deprivation and Cannabis Use in Explaining Variation in the Incidence of Psychotic Disorders: Findings From the EU-GEI Study.
Brink, Vera; Andleeb, Humma; Gayer-Anderson, Charlotte; Arango, Celso; Arrojo, Manuel; Berardi, Domenico; Bernardo, Miquel; Bobes, Julio; Del-Ben, Cristina Marta; Ferraro, Laura; de Haan, Lieuwe; La Barbera, Daniele; La Cascia, Caterina; Lasalvia, Antonio; Llorca, Pierre-Michel; Menezes, Paolo Rossi; Pignon, Baptiste; Sanjuán, Julio; Santos, José Luis; Selten, Jean-Paul; Tarricone, Ilaria; Tortelli, Andrea; Tripoli, Giada; Velthorst, Eva; Rutten, Bart P F; van Os, Jim; Quattrone, Diego; Murray, Robin M; Jones, Peter B; Morgan, Craig; Di Forti, Marta; Jongsma, Hannah E; Kirkbride, James B.
Affiliation
  • Brink V; Department of Psychosis, University Center Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Andleeb H; PsyLife Group, Division of Psychiatry, University College London, London, UK.
  • Gayer-Anderson C; PsyLife Group, Division of Psychiatry, University College London, London, UK.
  • Arango C; ESRC Centre for Society and Mental Health, King's College London, London, UK.
  • Arrojo M; Department of Health Service and Population Research, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Berardi D; Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM, CIBERSAM, Madrid, Spain.
  • Bernardo M; Department of Mental Health and Drug-Addiction Assistance, Health Service of Galicia, Psychiatric Genetic Group IDIS, Hospital Clínico Universitario de Santiago de Compostela, affiliated center to Centro de Investigación Biomédica en Red de Salud Mental, Servicio Gallego de Salud, Santiago de Compos
  • Bobes J; Alma Mater Studiorium Università di Bologna, Bologna, Italy.
  • Del-Ben CM; Barcelona Clinic Schizophrenia Unit, Hospital Clinic de Barcelona, Barcelona, Spain.
  • Ferraro L; Departament de Medicina, Institut de Neurociències (UBNeuro), Universitat de Barcelona (UB), Barcelona, Spain.
  • de Haan L; Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.
  • La Barbera D; CIBERSAM, ISCIII, Barcelona, Spain.
  • La Cascia C; Department of Medicine, Psychiatry Area, School of Medicine, Universidad de Oviedo, Centro de Investigación Biomédica en Red de Salud Mental, Oviedo, Spain.
  • Lasalvia A; Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
  • Llorca PM; Department of Biomedicine, Neuroscience, and Advanced Diagnostics, Section of Psychiatry, University of Palermo, Palermo, Italy.
  • Menezes PR; Department of Psychiatry, Early Psychosis Section, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
  • Pignon B; Department of Biomedicine, Neuroscience, and Advanced Diagnostics, Section of Psychiatry, University of Palermo, Palermo, Italy.
  • Sanjuán J; Department of Biomedicine, Neuroscience, and Advanced Diagnostics, Section of Psychiatry, University of Palermo, Palermo, Italy.
  • Santos JL; Department of Neuroscience, Biomedicine and Movement, Section of Psychiatry, University of Verona, Verona, Italy.
  • Selten JP; Fondation FondaMental, Créteil, France.
  • Tarricone I; CMP B CHU, Clermont-Ferrand, France.
  • Tortelli A; Université Clermont Auvergne, Clermont-Ferrand, France.
  • Tripoli G; Department of Preventive Medicine, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
  • Velthorst E; Núcleo de Pesquina em Saúde Mental Populacional, Universidade de São Paulo, São Paulo, Brazil.
  • Rutten BPF; Fondation FondaMental, Créteil, France.
  • van Os J; Université Paris-Est-Créteil (UPEC) and AP-HP, Hôpitaux Universitaires « H. Mondor ¼, DMU IMPACT, Psychiatry department and INSERM, IMRB, Translational Neuropsychiatry, Créteil, France.
  • Quattrone D; Department of Psychiatry, School of Medicine, Universidad de Valencia, Centro de Investigación Biomédica en Red de Salud Mental, Valencia, Spain.
  • Murray RM; Department of Psychiatry, Servicio de Psiquiatría Hospital "Virgen de la Luz", Cuenca, Spain.
  • Jones PB; Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Morgan C; Department of Medical and Surgical Science, Psychiatry Unit, Alma Mater Studiorium Università di Bologna, Bologna, Italy.
  • Di Forti M; Institut National de la Santé et de la Recherche Médicale, U955, Créteil, France.
  • Jongsma HE; Pôle Psychiatrie Précarité, Groupe Hospitalier Paris Psychiatrie Neurosciences, Paris, France.
  • Kirkbride JB; Department of Biomedicine, Neuroscience, and Advanced Diagnostics, Section of Psychiatry, University of Palermo, Palermo, Italy.
Schizophr Bull ; 50(5): 1039-1049, 2024 Aug 27.
Article in En | MEDLINE | ID: mdl-38788048
ABSTRACT
BACKGROUND AND

HYPOTHESIS:

Recent findings suggest the incidence of first-episode psychotic disorders (FEP) varies according to setting-level deprivation and cannabis use, but these factors have not been investigated together. We hypothesized deprivation would be more strongly associated with variation in FEP incidence than the prevalence of daily or high-potency cannabis use between settings. STUDY

DESIGN:

We used incidence data in people aged 18-64 years from 14 settings of the EU-GEI study. We estimated the prevalence of daily and high-potency cannabis use in controls as a proxy for usage in the population at-risk; multiple imputations by chained equations and poststratification weighting handled missing data and control representativeness, respectively. We modeled FEP incidence in random intercepts negative binomial regression models to investigate associations with the prevalence of cannabis use in controls, unemployment, and owner-occupancy in each setting, controlling for population density, age, sex, and migrant/ethnic group. STUDY

RESULTS:

Lower owner-occupancy was independently associated with increased FEP (adjusted incidence rate ratio [aIRR] 0.76, 95% CI 0.61-0.95) and non-affective psychosis incidence (aIRR 0.68, 95% CI 0.55-0.83), after multivariable adjustment. Prevalence of daily cannabis use in controls was associated with the incidence of affective psychoses (aIRR 1.53, 95% CI 1.02-2.31). We found no association between FEP incidence and unemployment or high-potency cannabis use prevalence. Sensitivity analyses supported these findings.

CONCLUSIONS:

Lower setting-level owner-occupancy and increased prevalence of daily cannabis use in controls independently contributed to setting-level variance in the incidence of different psychotic disorders. Public health interventions that reduce exposure to these harmful environmental factors could lower the population-level burden of psychotic disorders.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psychotic Disorders Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Schizophr Bull Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psychotic Disorders Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Schizophr Bull Year: 2024 Document type: Article